PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1α

Iris Eke, Ulrike Koch, Stephanie Hehlgans, Veit Sandfort, Fabio Stanchi, Daniel Zips, Michael Baumann, Anna Shevchenko, Christian Pilarsky, Michael Haase, Gustavo B. Baretton, Véronique Calleja, Banafshé Larijani, Reinhard Fässler, Nils Cordes

Research output: Contribution to journalArticlepeer-review

84 Citations (SciVal)


Tumor cell resistance to ionizing radiation and chemotherapy is a major obstacle in cancer therapy. One factor contributing to this is integrin-mediated adhesion to ECM. The adapter protein particularly interesting new cysteine-histidine-rich 1 (PINCH1) is recruited to integrin adhesion sites and promotes cell survival, but the mechanisms underlying this effect are not well understood. Here we have shown that PINCH1 is expressed at elevated levels in human tumors of diverse origins relative to normal tissue. Furthermore, PINCH1 promoted cell survival upon treatment with ionizing radiation in vitro and in vivo by perpetuating Akt1 phosphorylation and activity. Mechanistically, PINCH1 was found to directly bind to protein phosphatase 1α (PP1α) - an Akt1-regulating protein - and inhibit PP1α activity, resulting in increased Akt1 phosphorylation and enhanced radioresistance. Thus, our data suggest that targeting signaling molecules such as PINCH1 that function downstream of focal adhesions (the complexes that mediate tumor cell adhesion to ECM) may overcome radio- and chemoresistance, providing new therapeutic approaches for cancer.

Original languageEnglish
Pages (from-to)2516-2527
Number of pages12
JournalJournal of Clinical Investigation
Issue number7
Publication statusPublished - 1 Jul 2010

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1α'. Together they form a unique fingerprint.

Cite this